INSM Insider: 56,520 Options Exercised; 76,520 Shares Sold Under 10b5-1
Rhea-AI Filing Summary
INSMED Inc (INSM) reporting person S. Nicole Schaeffer, Chief People Strategy Officer, completed multiple transactions on 09/12/2025 under a 10b5-1 plan. She exercised 56,520 stock options with a $23.75 exercise price, resulting in ownership of 56,520 shares from the exercise and a reported pre-sale beneficial ownership of 112,981 shares. On the same date she sold a total of 76,520 shares in four separate sell transactions at weighted average prices of $144.6, $145.67, $146.57, and $147.46, leaving her with 36,461 shares beneficially owned following the reported transactions. The sales were effected pursuant to a 10b5-1 trading plan adopted June 13, 2025, and the filing is signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Option exercise at $23.75 yielded a substantial gain opportunity given subsequent sale prices above $144 per share.
- Transactions effected under a 10b5-1 trading plan, indicating pre-established, rule-compliant disposition of shares.
Negative
- Large net reduction in beneficial ownership: beneficial shares fell to 36,461 after selling 76,520 shares.
- Significant volume sold on single date (76,520 shares) could be perceived negatively by some investors monitoring insider holdings.
Insights
TL;DR: Officer exercised options at $23.75 then sold most shares under a 10b5-1 plan, reducing beneficial ownership materially.
The filing shows an in-the-money option exercise converting 56,520 options into shares at a low exercise price of $23.75, followed by contemporaneous market sales of 76,520 shares at weighted average prices between $144.06 and $148.00 per share under a 10b5-1 plan adopted June 13, 2025. The net effect is a reduction in reported beneficial ownership to 36,461 shares. These are routine, pre-planned transactions rather than ad hoc dispositions; materiality lies in the size of the sales relative to the reporting person's prior ownership.
TL;DR: Transactions appear compliant with Rule 10b5-1; documentation notes weighted-average pricing disclosures and attorney-in-fact signature.
The Form 4 discloses adoption of a 10b5-1 plan (June 13, 2025) and provides weighted-average sale price ranges with commitments to provide per-price breakdowns on request, which aligns with disclosure norms. The filing is executed by an attorney-in-fact, and option vesting details are provided. No indications of insider timing or amendments are present in the filing; the pattern is consistent with pre-arranged liquidity planning by an executive.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 56,520 | $0.00 | $0.00 |
| Exercise | Common Stock | 56,520 | $23.75 | $1.34M |
| Sale | Common Stock | 32,091 | $144.60 | $4.64M |
| Sale | Common Stock | 30,967 | $145.67 | $4.51M |
| Sale | Common Stock | 7,304 | $146.57 | $1.07M |
| Sale | Common Stock | 6,158 | $147.46 | $908K |
Footnotes (6)
- F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- F2. This is the weighted average sales price representing 32,091 shares sold at prices ranging from $144.06 to $145.05 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F3. This is the weighted average sales price representing 30,967 shares sold at prices ranging from $145.06 to $146.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F4. This is the weighted average sales price representing 7,304 shares sold at prices ranging from $146.08 to $147.06 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F5. This is the weighted average sales price representing 6,158 shares sold at prices ranging from $147.12 to $148.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
- F6. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.